Hello everyone!
My name is Chris Winchester and I am a co-Founder of Open Pharma, an initiative to advance the publication of pharmaceutical and biotech company results. Pharmaceutical companies now publish essentially all of their clinical trials but many of the results are stuck behind paywalls. To achieve 100% open access, they will have to persuade some of the world's most influential journals to change their policies, and offer them the same opportunity to publish open access as non-commercial funders such as the National Institutes of Health, the Gates Foundation and Wellcome Trust.
If you think 100% OA is a goal worth fighting for, tell us why! What tangible difference does it make to have open access to published clinical trials results? What problems does it cause you and those around you when such results are stuck behind a paywall? We'd love to hear your experiences.
Chris Winchester DPhil (he/him)
Chief Executive Officer
Let us know how we're doing <https://forms.office.com/Pages/ResponsePage.aspx?id=o-yV6kVaqUK4yzaYHLKc...
Oxford PharmaGenesis Ltd
UK Tel: +44 1865 390144
Mobile: +44 7803 196998
chris.winchester@pharmagenesis.com
PA: Claire Kimber claire.kimber@pharmagenesis.com
www.pharmagenesis.com<http://www.pharmagenesis.com/>
Oxford PharmaGenesis Ltd is registered in England and Wales, registration number 03488862. Our registered office is at Tubney Warren Barn, Tubney, Oxford, OX13 5QJ, UK.
HIFA profile: Chris Winchester DPhil is CEO of Oxford PharmaGenesis, an award-winning, independent HealthScience communications consultancy with 500 employees in Europe, North America and Asia Pacific. The company helps its clients in pharmaceutical and biotech companies communicate the evidence behind new drugs and vaccines to healthcare professionals, payers and patients. Chris is a Co-founder of Open Pharma, a Director of Oxford Health Policy Forum CIC and an Associate Fellow of Green Templeton College, Oxford. He is a member of the HIFA working group on open access. https://www.hifa.org/support/members/chris-3 chris.winchester AT pharmagenesis.com